Achieve Life Sciences (NASDAQ:ACHV) Given Outperform Rating at Oppenheimer

Oppenheimer restated their outperform rating on shares of Achieve Life Sciences (NASDAQ:ACHV) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $18.00 price target on the biopharmaceutical company’s stock.

Separately, Lake Street Capital lowered their price target on shares of Achieve Life Sciences from $19.00 to $11.00 and set a buy rating for the company in a research report on Tuesday, March 5th.

Achieve Life Sciences Trading Up 0.8 %

Shares of NASDAQ ACHV opened at $4.58 on Monday. Achieve Life Sciences has a 1-year low of $3.03 and a 1-year high of $10.30. The company has a market cap of $96.96 million, a PE ratio of -2.99 and a beta of 1.32. The company has a current ratio of 5.36, a quick ratio of 5.36 and a debt-to-equity ratio of 4.02. The company has a 50-day moving average of $4.50 and a two-hundred day moving average of $4.40.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its holdings in Achieve Life Sciences by 75.6% during the first quarter. Tower Research Capital LLC TRC now owns 3,646 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 1,570 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Achieve Life Sciences by 6.1% in the first quarter. Renaissance Technologies LLC now owns 41,600 shares of the biopharmaceutical company’s stock valued at $283,000 after buying an additional 2,400 shares during the period. State Street Corp boosted its holdings in shares of Achieve Life Sciences by 26.9% in the first quarter. State Street Corp now owns 18,731 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 3,970 shares during the period. Northern Trust Corp boosted its holdings in shares of Achieve Life Sciences by 7.3% in the third quarter. Northern Trust Corp now owns 78,957 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 5,379 shares during the period. Finally, Manchester Financial Inc. boosted its holdings in shares of Achieve Life Sciences by 43.9% in the third quarter. Manchester Financial Inc. now owns 18,600 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 5,675 shares during the period. Institutional investors and hedge funds own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.